Flagship Pioneering, a scientific innovation engine for transformative platforms and products, announced on Thursday that ProFound Therapeutics and Quotient Therapeutics have entered into feasibility agreements with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to discover and validate novel targets and therapeutic approaches in respiratory and liver diseases.

These are the first company-focused agreements signed under the framework collaboration between Flagship and GSK to combine GSK's disease area expertise and development capabilities with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies.

Paul Biondi, Flagship Pioneering managing partner, said: "Flagship Pioneering and GSK have a shared mission to accelerate the development of breakthrough medicines for patients with the greatest unmet needs by combining innovative new technologies with deep drug development expertise. These agreements bring together two pioneering approaches to advance innovative treatments for respiratory and liver diseases, and to identify novel and differentiated targets that may alter the course of disease."